Literature DB >> 20505659

Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis.

Elizabeth M Jarvis1, Carmel M Hawley, Stephen P McDonald, Fiona G Brown, Johan B Rosman, Kathryn J Wiggins, Kym M Bannister, David W Johnson.   

Abstract

Non-Pseudomonas Gram-negative (NPGN) peritonitis is a frequent, serious complication of peritoneal dialysis; however, previous reports have been limited to small, single-center studies. To gain insight on the frequency, predictors, treatment, and outcomes of NPGN peritonitis, we analyzed data in the ANZDATA registry of all adult Australian peritoneal dialysis patients over a 39-month period using multivariate logistic and multilevel Poisson regressions. There were 837 episodes of NPGN peritonitis (23.3% of all peritonitis) that occurred in 256 patients. The most common organism isolated was Escherichia coli, but included Klebsiella, Enterobacter, Serratia, Acinetobacter, Proteus, and Citrobacter, with multiple organisms identified in a quarter of the patients. The principal risk factor was older age, with poorer clinical outcome predicted by older age and polymicrobial peritonitis. The overall antibiotic cure rate was 59%. NPGN peritonitis was associated with significantly higher risks of hospitalization, catheter removal, permanent transfer to hemodialysis, and death compared to other organisms contributing to peritonitis. Underlying bowel perforation requiring surgery was uncommon. Hence, we show that NPGN peritonitis is a frequent, serious complication of peritoneal dialysis, which is frequently associated with significant risks, including death. Its cure with antibiotics alone is less likely when multiple organisms are involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505659     DOI: 10.1038/ki.2010.149

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

1.  Weekend compared with weekday presentations of peritoneal dialysis-associated peritonitis.

Authors:  David W Johnson; Philip Clayton; Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen McDonald; Neil Boudville; Kathryn J Wiggins; Kym Bannister; Fiona Brown
Journal:  Perit Dial Int       Date:  2012-02-01       Impact factor: 1.756

2.  The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis.

Authors:  Wen Tang; Yeoungjee Cho; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

3.  Is female sex really a risk factor for infectious death in peritoneal dialysis?

Authors:  David W Johnson; Yeoungjee Cho; Rajnish Mehrotra
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

4.  Changes in serum albumin concentrations during transition to dialysis and subsequent risk of peritonitis after peritoneal dialysis initiation: a retrospective cohort study.

Authors:  Kajohnsak Noppakun; Thanit Kasemset; Uraiwan Wongsawad; Chidchanok Ruengorn; Kednapa Thavorn; Manish M Sood; Surapon Nochaiwong
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902

Review 5.  The Current State of Peritoneal Dialysis.

Authors:  Rajnish Mehrotra; Olivier Devuyst; Simon J Davies; David W Johnson
Journal:  J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 10.121

Review 6.  Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand.

Authors:  Melissa Nataatmadja; Yeoungjee Cho; David W Johnson
Journal:  Perit Dial Int       Date:  2016-09-10       Impact factor: 1.756

Review 7.  Infectious complications in dialysis--epidemiology and outcomes.

Authors:  Philip Kam-Tao Li; Kai Ming Chow
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

8.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

9.  Is transition between peritoneal dialysis and hemodialysis really a gradual process?

Authors:  Lucie Boissinot; Isabelle Landru; Eric Cardineau; Elie Zagdoun; Jean-Philippe Ryckelycnk; Thierry Lobbedez
Journal:  Perit Dial Int       Date:  2013-01-02       Impact factor: 1.756

10.  The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.

Authors:  Lei Zhang; Sunil V Badve; Elaine M Pascoe; Elaine Beller; Alan Cass; Carolyn Clark; Janak de Zoysa; Nicole M Isbel; Steven McTaggart; Alicia T Morrish; E Geoffrey Playford; Anish Scaria; Paul Snelling; Liza A Vergara; Carmel M Hawley; David W Johnson
Journal:  Perit Dial Int       Date:  2015-07-29       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.